The article explores the complex relationship between inflammation and cancer, highlighting the role of chronic inflammation in the onset and progression of various diseases, including neurodegenerative and cardiovascular diseases, diabetes, and cancer. It emphasizes that at least 20% of breast and colorectal cancers are associated with chronic inflammation triggered by infections, irritants, or autoimmune diseases. The article discusses the importance of maintaining a healthy body weight and adopting an anti-inflammatory diet to disrupt this axis. It also reviews the potential of natural products and their derivatives as antitumor agents, noting the challenges in developing natural bioactive drugs due to their variability and complexity. The review further examines the clinical utility of combining anti-inflammatory products, such as non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and statins, with plant-derived products to enhance traditional therapeutic approaches. The article highlights the need for comprehensive strategies in cancer therapy, considering the systemic and multifactorial nature of inflammation. It also underscores the importance of understanding genetic variability, environmental exposure, dietary habits, and the tumor microenvironment (TME) to establish therapeutic approaches based on molecular and genetic analysis. Additionally, the article explores the potential of endocannabinoid, cannabinoid, and prostamide-type compounds as therapeutic targets or biomarkers in cancer treatment.The article explores the complex relationship between inflammation and cancer, highlighting the role of chronic inflammation in the onset and progression of various diseases, including neurodegenerative and cardiovascular diseases, diabetes, and cancer. It emphasizes that at least 20% of breast and colorectal cancers are associated with chronic inflammation triggered by infections, irritants, or autoimmune diseases. The article discusses the importance of maintaining a healthy body weight and adopting an anti-inflammatory diet to disrupt this axis. It also reviews the potential of natural products and their derivatives as antitumor agents, noting the challenges in developing natural bioactive drugs due to their variability and complexity. The review further examines the clinical utility of combining anti-inflammatory products, such as non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and statins, with plant-derived products to enhance traditional therapeutic approaches. The article highlights the need for comprehensive strategies in cancer therapy, considering the systemic and multifactorial nature of inflammation. It also underscores the importance of understanding genetic variability, environmental exposure, dietary habits, and the tumor microenvironment (TME) to establish therapeutic approaches based on molecular and genetic analysis. Additionally, the article explores the potential of endocannabinoid, cannabinoid, and prostamide-type compounds as therapeutic targets or biomarkers in cancer treatment.